Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4816 AL 4830

Alzheimer's Disease: Genomics and Beyond

Song F, Han G, Bai Z, Peng X, Wang J, Lei H.

Int Rev Neurobiol. 2015;121:1-24. doi: 10.1016/bs.irn.2015.05.001. Epub 2015 Jun 19.

Hybrids: a new paradigm to treat Alzheimer's disease

Singh M, Kaur M, Chadha N, Silakari O.

Mol Divers. 2016 Feb;20(1):271-97. doi: 10.1007/s11030-015-9628-9. Epub 2015 Sep 2.

Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Br J Pharmacol. 2016 Jul;173(13):2080-94. doi: 10.1111/bph.13318. Epub 2015 Dec 1.

The Impact of Docosahexaenoic Acid on Alzheimer's Disease: Is There a Role of the Blood-Brain Barrier?

Pan Y, Khalil H, Nicolazzo JA.

Curr Clin Pharmacol. 2015;10(3):222-41. doi: 10.2174/157488471003150820151532.

Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease

Fonseca-Santos B, Gremião MP, Chorilli M.

Int J Nanomedicine. 2015 Aug 4;10:4981-5003. doi: 10.2147/IJN.S87148. eCollection 2015.

The problem of genotype and sex differences in life expectancy in transgenic AD mice

Rae EA, Brown RE.

Neurosci Biobehav Rev. 2015 Oct;57:238-51. doi: 10.1016/j.neubiorev.2015.09.002. Epub 2015 Sep 6.

Pressure ulcers induced by drug administration: A new concept and report of four cases in elderly patients

Mizokami F, Takahashi Y, Hasegawa K, Hattori H, Nishihara K, Endo H, Furuta K, Isogai Z.

J Dermatol. 2016 Apr;43(4):436-8. doi: 10.1111/1346-8138.13093. Epub 2015 Sep 14.

Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease

Isaacson RS, Ferris S, Velting DM, Meng X.

Am J Alzheimers Dis Other Demen. 2016 May;31(3):270-7. doi: 10.1177/1533317515603687. Epub 2015 Sep 14.

Why therapies for Alzheimer's disease do not work: Do we have consensus over the path to follow?

Amtul Z.

Ageing Res Rev. 2016 Jan;25:70-84. doi: 10.1016/j.arr.2015.09.003. Epub 2015 Sep 12.

Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease

Parker CA, Rabiner EA, Gunn RN, Searle G, Martarello L, Comley RA, Davy M, Wilson AA, Houle S, Mizrahi R, Laruelle M, Cunningham VJ.

J Nucl Med. 2015 Dec;56(12):1901-9. doi: 10.2967/jnumed.115.162743. Epub 2015 Sep 17.

Vascular pathology: Cause or effect in Alzheimer disease?

Rius-Pérez S, Tormos AM, Pérez S, Taléns-Visconti R.

Neurologia (Engl Ed). 2018 Mar;33(2):112-120. doi: 10.1016/j.nrl.2015.07.010. Epub 2015 Sep 16.

Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases

Cholia RP, Nayyar H, Kumar R, Mantha AK.

Curr Mol Med. 2015;15(10):932-43. doi: 10.2174/1566524015666150921104804.

Potential drug-drug interactions in Alzheimer patients with behavioral symptoms

Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F.

Clin Interv Aging. 2015 Sep 8;10:1457-66. doi: 10.2147/CIA.S87466. eCollection 2015.

A Review of Pharmacological Treatments for Depression in Alzheimer's Disease

Siarkos KT, Katirtzoglou EA, Politis AM.

J Alzheimers Dis. 2015;48(1):15-34. doi: 10.3233/JAD-148010.

Repetitive Transcranial Magnetic Stimulation as an Alternative Therapy for Cognitive Impairment in Alzheimer's Disease: A Meta-Analysis

Liao X, Li G, Wang A, Liu T, Feng S, Guo Z, Tang Q, Jin Y, Xing G, McClure MA, Chen H, He B, Liu H, Mu Q.

J Alzheimers Dis. 2015;48(2):463-72. doi: 10.3233/JAD-150346.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias